论文部分内容阅读
目的:分析新型靶向药物拉帕替尼对人卵巢癌细胞SKOV3的影响,评价拉帕替尼在卵巢癌治疗中的价值。方法:采用体外实验研究,培养人卵巢癌细胞株SKOV3,进行分组,包括低中高实验组、对照组、模型组,采用流式细胞仪分析细胞周期,采用MTT方法检测细胞活力。结果:实验组人卵巢癌细胞SKOVS细胞活力、细胞周期与对照组、模型组组间比较存在显著差异(P<0.05),低、中、高剂量实验组指标呈现阶梯变化。结论:拉帕替尼对人卵巢癌细胞SKOV3细胞增殖具有明显的抑制作用,且呈现剂量依赖。
OBJECTIVE: To analyze the effect of lapatinib on human ovarian cancer cell line SKOV3 and to evaluate the value of lapatinib in the treatment of ovarian cancer. Methods: Human ovarian cancer cell line SKOV3 was cultured in vitro, including low, middle and high experimental groups, control group and model group. Cell cycle was analyzed by flow cytometry and cell viability was detected by MTT assay. Results: The cell viability and cell cycle of SKOVS cells in experimental group were significantly different from those in control group and model group (P <0.05). The indexes of experimental group showed a step change. Conclusion: Lapatinib has a significant inhibitory effect on the proliferation of human ovarian cancer SKOV3 cells in a dose-dependent manner.